Since targeting TRPM2 has potential in the treatment of a wide variety of CNS diseases, including ischemia/stroke, Alzheimer's disease, neuropathic pain, bipolar disorder, and Parkinson's disease, great efforts have been made to develop TRPM2 specific inhibitors for the past decades although progress has been slow.[3, 4, 6] Unfortunately, these have not been specifically developed for the purpose of cancer treatment, implying that they may not be optimized for cancer treatment. This evidence concerns the gene TRPM2 and Stroke.